Chronic Myeloid Leukemia, Complete Molecular Response, Imatinib
Conditions
Brief summary
This prospective study is performed to identify safer and more concrete indicators of successful discontinuation and explore contributing factors for sustained undetectable transcript
Detailed description
Imatinib (IM) treatment has been the standard of care for chronic phase (CP) chronic myeloid leukemia (CML) and approximately 50% of CP CML patients who received IM treatment achieve complete molecular response (CMR) at 6-7 years.(Hochhaus A et al. Leukemia 2009;23:1054-1061, Hughes et al. Blood 2008;112:334) The recent data from a study aimed to assess whether IM can be discontinued in patients with a CMR lasting at least 2 years showed the probability of persistent CMR at 12 months was 41%, and suggested IM can be safely discontinued, at least in some patients with sustained CMR. (Mahon et al. Lancet Oncol 2010;11:1029-1035) However, to define whether discontinuation of IM treatment can be safely employed, further validation and much longer follow-up are needed. Aims This prospective study is performed to identify safer and more concrete indicators of successful discontinuation and explore contributing factors for sustained undetectable transcript. Primary Objective: * To evaluate the probability of persistent undetectable molecular residual disease (UMRD) and MR4.5 at 12 months after discontinuation * To measure the duration of persistent UMRD and MR4.5 after discontinuation * To identify contributing factors for sustained undetectable transcript Secondary Objective: * To evaluate the probability of major molecular response (MMR) loss * To evaluate the time taken to lose MMR at 12 months after discontinuation * In patients with loss of MMR, the probability of re-achieving MMR/MR4.5 * To measure the time taken to re-achieve MMR/MR4.5 after IM resumption * To identify contributing factors for sustained re-achieve MMR/MR4.5 Trial Design This is a prospective, multicenter, non-randomised IM discontinuation study. Response Evaluation After discontinuation, molecular response was monitored using RQ-PCR assay every month up to 6 month follow-up, every 2 months up to 12 month follow-up, and every 3 months thereafter. The loss of MMR, MR4.5, and UMRD were defined on 2 consecutive assessments. If loss of MMR occurred, IM treatment was re-introduced. Written informed consents were obtained for all patients
Interventions
BEHAVIORALImatinib treatment discontinuing
Ph+ CP CML patients who were treated with IM for more than 3 years in sustained MR4.5 or undetectable transcript for at least 2 years are enrolled
Sponsors
Ministry of Health & Welfare, Korea
Seoul St. Mary's Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Adult (≥ 18 years-old) Ph+ CP CML patients who were treated with IM for more than 3 years in sustained MR4.5 or undetectable transcript for at least 2 years are enrolled. MR4.5 or undetectable transcript must be sustained by 2 consecutive RQ-PCR assay within 6 months
Exclusion criteria
* Patients were diagnosed with AP or BP CML * Ph+ ALL * Received cytotoxic chemotherapy or any other TKIs except imatinib * Any evidence of on-going graft versus-host disease (GVHD) * Relapsed patients after allogeneic stem cell transplantation
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Probability of persistent undetectable molecular residual disease (UMRD) and MR4.5 | 12 months | Our primary objectives were to evaluate the probability of persistent undetectable molecular residual disease (UMRD) and MR4.5 at 12 months after discontinuation, to measure the duration of persistent UMRD and MR4.5 after discontinuation, and to identify contributing factors for sustained undetectable transcript. |
Countries
South Korea
Contacts
Primary ContactSahee Park, MS
Outcome results
None listed